The American laboratory Pfizer announced on Tuesday that its pill against the coronavirus decreases almost 90% risk of hospitalization or death among patients at high risk of developing severe forms of the disease, according to a clinical trial.
The results are based on tests from all participants in the medical study – more than 2,200 people – and confirm what was announced in early November based on preliminary conclusions.
In clinical studies carried out by the pharmacist, the risk reduction hospitalization or death from coronavirus was 89% when the pill was administered within three days of the first symptoms. Meanwhile, the efficacy was 88% when it was administered in the five days after the first physical signs of having contracted this disease.
The study was carried out among 2,246 adults residents of North and South America, Europe, Africa and Asia (41% of them in the United States) who had been diagnosed with Covid-19 in the previous five days. Furthermore, all medical trial participants had at least one characteristic or medical condition that made them patients at risk of developing serious disease.
The US pharmaceutical company announced that it hopes that its antiviral treatment, which will be marketed as Paxlovid, will continue to be effective against the Omicron variant.
Of all the patients who received Paxlovid, only 0.7% were hospitalized within 28 days of their participation in the study, and none of them died.
In contrast, among those patients who participated in the study but to those who were not given Paxlovid, 6.5% were hospitalized or died, Pfizer reported.
Pfizer hopes that its antiviral treatment, which will be marketed as Paxlovid, will continue to be effective against the Omicron variant. Photo: Reuters
In a statement, Pfizer indicated that its most recent data confirms that the drug is a “strong inhibitor” against the Omicron variant of the coronavirus.
Paxlovid tablets have not yet been approved by the US Food and Drug Administration (FDA), but Pfizer CEO Albert Bourla was hopeful in early December that the drug could be received. Okay before the end of the month.
Albert Bourla highlighted the “potential” of the drug as a “candidate to save the lives of patients around the world.”
“Worrisome variants like Ómicron have exacerbated the need for accessible treatment options for those who contract the virus, “added Bourla.
Antivirals, which work by decreasing the ability of a virus to replicate, represent a key complement to vaccines for protection against COVID-19, particularly because they are so easy to administer.
With information from AFP and EFE